Intellicyt
Acquired10,112 employees on LinkedIn · 1 known investors
Intellicyt (now part of Sartorius) develops the iQue high-throughput screening (HTS) flow cytometry platform, which combines sampling hardware and analysis software to generate multiplexed cell phenotype and function data from 96- or 384-well plates. It serves life science researchers working in areas such as antibody discovery, T-cell engineering, and immuno-oncology.
Investors · 1
Frequently asked questions
- What does Intellicyt do?
- Intellicyt (now part of Sartorius) develops the iQue high-throughput screening (HTS) flow cytometry platform, which combines sampling hardware and analysis software to generate multiplexed cell phenotype and function data from 96- or 384-well plates. It serves life science researchers working in areas such as antibody discovery, T-cell engineering, and immuno-oncology.
- Who are Intellicyt's investors?
- Intellicyt's investors include Saba Investments.